Catalog No.: PC-35927Not For Human Use, Lab Use Only.
RRx-001 (RRx001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity, RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α.
RRx-001 (RRx001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity, RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α.
RRX-001 targets CD133 + /CD44 + cancer stem cells from colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc.
RRX-001 inhibits HCT 116 and decreases levels of the DNA methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner.
RRX-001 (RRX001) is a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia.
